TY - JOUR
T1 - Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma
T2 - Immunohistochemical analysis of 76 cases of low and high-grade meningioma
AU - Kato, Yasutaka
AU - Nishihara, Hiroshi
AU - Mohri, Hiromi
AU - Kanno, Hiromi
AU - Kobayashi, Hiroyuki
AU - Kimura, Taichi
AU - Tanino, Mishie
AU - Terasaka, Shunsuke
AU - Tanaka, Shinya
N1 - Funding Information:
We thank Dr Tamio Itoh (Nakamura Memorial Hospital), Dr Masahito Kato (Hokkaido neurosurgical memorial hospital), Dr Shin Fujimoto (Kashiwaba Neurosurgical Hospital), and Dr Junichi Murata (Sapporo Azabu neurosurgical hospital) for providing clinical data for this analysis. This research was supported by a Grant-in-Aid for Scientific Research (KAKENHI) and by the Japan Society for the Promotion of Science (JSPS) through the “Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)”, initiated by the Council for Science and Technology Policy (CSTP).
PY - 2014/1
Y1 - 2014/1
N2 - Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30% of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade ( P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.
AB - Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30% of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade ( P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.
KW - Clinicopathological analysis
KW - Cyclooxygenase-2
KW - Immunohistochemistry
KW - Meningioma
UR - http://www.scopus.com/inward/record.url?scp=84895865293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895865293&partnerID=8YFLogxK
U2 - 10.1007/s10014-012-0127-8
DO - 10.1007/s10014-012-0127-8
M3 - Article
C2 - 23250387
AN - SCOPUS:84895865293
SN - 1433-7398
VL - 31
SP - 23
EP - 30
JO - Brain Tumor Pathology
JF - Brain Tumor Pathology
IS - 1
ER -
